Continued miniaturisation of assay technologies drives market for nanolitre dispensing By Dr John Comley The continued miniaturisation of assay technologies in high throughput screening, compound management and protein crystallisation has created a pressing need for improved nanolitre liquid handling systems. A recent industry… Read More
By Dr Peter C. Johnson and Dr Alan J. Higgins The pharmaceutical industry has not seen the hoped-for productivity gains from the various omics datastreams over the last decade. This article discusses how systems biology can exploit the natural interlinkages between these datastreams and put in… Read More
The Current Bioinformatics Analytical Software Landscape By Charles Chang With the vast amount of biochemical data generated from experiments conducted by research laboratories around the globe, there is strong demand for software to analyse and manage the data effectively. Analytical software can be utilised… Read More
Growing Market for High Content Analysis Tools By Dr. John Comley and Sandra Fox Two market surveys and a recent major scientific meeting have all highlighted the growing interest in High Content Screening (HCS) and point to the momentum which now surrounds the implementation of high content analysis… Read More
Functional cell-based high throughput drug screening By Professor Daniel T. Chiu and Professor Owe Orwar Cell-based assays are poised to assume an increasingly important role in drug screening and discovery. It is becoming apparent that simple binding assays and in vitro experiments are grossly insufficient for extrapolating… Read More
Making the Most of Drug Discovery Data By Dr Nick Davies and Dr Tim Peakman Discovery scientists in most pharmaceutical companies are struggling with incompatible legacy systems, a growing volume of data and the imminent advent of a product model that will demand much more of them. Read More
Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library By Andrea Kroenke, Anne Grabner, Dr Michael Hannus, Dr Christoph Sachse, Dr David Dorris and Dr Christophe Echeverri Libraries of siRNAs directed against predefined subsets of genes now offer the capacity… Read More
Role of image informatics in accelerating drug discovery and development By Robert Dunkle There is a new category of informatics that is proving itself essential to the acceleration of drug discovery and development. Image informatics is the systematic use of image data as a means to help interpret… Read More
New Flash Imagers: Facilitating higher throughput functional GPCR assays By Dr John Comley The recent availability of tailored automation solutions that combine liquid handling at the reading position with the latest innovations in low light imaging technology are providing screeners with new tools for the measurement of… Read More
Accommodating cells in HTS By Sandra Fox High Throughput Screening has become an important and integrated part of drug discovery at most pharmaceutical and many biotechnology companies worldwide, and is now entrenched in the drug discovery process. To produce high quality leads, centralised HTS… Read More
By Tim Ward Cell culture is and has historically been an essential component of the drug discovery toolbox. Cell culture provides the proteins, membrane preparations and other raw materials required for biological research. In recent years, with the emergence of high-throughput… Read More
PATCHERS vs SCREENERS: divergent opinion on high throughput electro-physiology By Dr John Comley The prospect of enabling higher throughput electro-physiology (patch-clamping) has created much expectation from scientists within the ion channel community. Yet there are opposing views among traditional electro-physiologists and screeners as to the needed specification and… Read More
By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease… Read More
The Industrial Evolution of Screening Infrastructure By Chris Molloy Industrialisation of screening depends upon the use of a stable,mature infrastructure. According to a recent Boston Consulting Group report, a pharmaceutical company needs to spend 900 million ($810 million) on R&D to bring a product to market. Read More
Synthetic approaches to rational drug design – A changing landscape By Dr Shubh Sharma and Dr Carl Spana It is becoming clearer that newer synthetic approaches for rational drug design may hold the promise of taking us closer to industrialising drug discovery while, at the same time, overcoming… Read More
High Throughput Screening using G-protein coupled receptors as the target plate-based and biochromatographic technologies By Professor Irving W.Wainer, Dr Farideh Beigi and Dr Ruin Moaddel The G-protein coupled receptor (GPCR) family constitutes the largest class of cell surface receptors and GPCRs are the targets for more than… Read More